Skip to main content
    M

    MoonLake Immunotherapeutics (MLTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.73
    -0.77 (-6.16%)

    Market Cap: $1.06B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MoonLake Immunotherapeutics (MLTX) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to MoonLake Immunotherapeutics are Tourmaline Bio (TRML), Immix Biopharma (IMMX) and Inhibrx Biosciences (INBX). By market cap, MoonLake Immunotherapeutics ranks 8th of the 13 companies on this page; Immunocore Holdings (IMCR) is the largest at $1.55B.

    Peer Comparison

    MLTX's ROIC of -54.6% is below the peer median of -14.9%, and its revenue growth of 0.0% is in line with the median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    MoonLake Immunotherapeutics (MLTX)$1.06BN/AN/A0.0%-54.6%0.0%0.00%
    Tourmaline Bio Inc. (TRML)$1.23BN/AN/A0.0%N/A0.0%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Inhibrx Biosciences, Inc. (INBX)$1.23BN/A610.4x0.0%-66.0%-100.0%0.00%
    Jade Biosciences, Inc. (JBIO)$1.03BN/AN/A0.0%N/A0.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Immatics NV (IMTX)$972.99MN/A17.7x0.0%N/A33.5%0.00%
    Immunocore Holdings Ltd (IMCR)$1.55BN/A2.8x-7.5%-0.5%-1.4%0.00%
    Intellia Therapeutics Inc (NTLA)$1.36BN/A26.1x0.0%-50.0%-48.0%0.00%
    MannKind Corp (MNKD)$1.33BN/A3.1x-18.1%-10.4%24.0%0.00%
    Rigel Pharmaceuticals Inc (RIGL)$837.18M14.2x2.8x106.6%16.7%16.5%0.00%
    Ocular Therapeutix Inc (OCUL)$1.37BN/A26.9x0.0%-52.1%-11.5%0.00%
    Surrozen Inc (SRZN)$602.54MN/A36.1x0.0%N/A408.6%0.00%
    Peer median$1.23B14.2x21.9x0.0%-14.9%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to MoonLake Immunotherapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Tourmaline Bio Inc. (TRML)
    Tourmaline Bio Inc. is a pioneering biotechnology firm dedicated to developing cutting-edge cell therapies targeting severe and life-threatening conditions...
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Inhibrx Biosciences, Inc. (INBX)
    Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates.
    INBX competitors
    Jade Biosciences, Inc. (JBIO)
    Jade Biosciences, Inc. is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune...
    JBIO competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Immatics NV (IMTX)
    Immatics NV, a clinical-stage biopharmaceutical company, focuses on the discovery and development of T-cell receptor (TCR) -based immunotherapies...
    IMTX competitors
    Immunocore Holdings Ltd (IMCR)
    Immunocore Holdings Limited, an advanced stage biotechnology company, develops immunotherapies for the treatment of cancer, infectious and autoimmune diseases.
    IMCR competitors
    Intellia Therapeutics Inc (NTLA)
    Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
    NTLA competitors
    MannKind Corp (MNKD)
    MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutics for endocrine and orphan lung...
    MNKD competitors
    Rigel Pharmaceuticals Inc (RIGL)
    Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases.
    RIGL competitors
    Ocular Therapeutix Inc (OCUL)
    Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development...
    OCUL competitors
    Surrozen Inc (SRZN)
    Surrozen Inc. is a clinical-stage biopharmaceutical company at the forefront of developing innovative therapeutics using its proprietary SIRPa-IgG platform...
    SRZN competitors

    Frequently Asked Questions About MLTX

    Who are MoonLake Immunotherapeutics' main competitors?

    The companies most similar to MoonLake Immunotherapeutics include Tourmaline Bio (TRML), Immix Biopharma (IMMX), Inhibrx Biosciences (INBX), Jade Biosciences (JBIO) and Structure Therapeutics Inc. American Depositary Shares (GPCR), listed from the closest match.

    Who is MoonLake Immunotherapeutics' biggest competitor?

    Immunocore Holdings (IMCR) is the largest of the similar companies at $1.55B; Tourmaline Bio (TRML) is the closest match by business profile, size, sector and industry.

    How does MLTX stock compare with its competitors?

    MLTX's net margin is 0.0% against a peer median of 0.0%.

    Which of MoonLake Immunotherapeutics' competitors pays a higher dividend?

    MoonLake Immunotherapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is MoonLake Immunotherapeutics bigger than its competitors?

    No. MoonLake Immunotherapeutics is 8th by market cap among the 13 companies on this page; the largest is Immunocore Holdings (IMCR) at $1.55B.